Influence of H. pylori eradication on liver function and metabolic profile in NASH patients

Compared to the standard NASH treatment protocol alone, the H. pylori eradication treatment + standard NASH treatment exhibited superior therapeutic effects in terms of reduction of fasting blood sugar in people with dyspeptic non-diabetic NASH.

A randomized clinical trial was conducted to assess the influence of Helicobacter pylori (H. pylori) elimination on liver fat content (LFC) and liver function tests (LFT) in non-diabetic non-alcoholic steatohepatitis (NASH).

Overall, 40 dyspeptic H. pylori people (mean age = 41.58 years) suffering from non-diabetic NASH were included and segregated into 2 groups. Participants in the treatment group (n = 20) were given H. pylori eradication intervention.  On the other hand, volunteers in the control group (n = 20) were not given any H. pylori intervention.

Meanwhile, the standard NASH management was carried out in both groups. The major endpoints were the mean alterations in LFT. The mean alteration in serum metabolic profile and LFC were the secondary endpoints ascertained. The follow-up duration was five years.

In both research groups, a profound reduction in mean serum alanine aminotransferase, fasting blood sugar (FBS), triglyceride, cholesterol, and elevation in high-density lipoprotein was observed in the tests of within-subject effects during the trial. The tests of between-subjects effects revealed a more remarkable decrease of FBS in H. pylori eliminated people when compared to the control group.

The decrease in LFC, insulin, low-density lipoprotein, cholesterol, triglyceride, alkaline phosphatase, ALT, aspartate aminotransferase, and waist circumference were more prominent in the treatment group compared to controls. But, these differences were not statistically profound.

Addition of H. pylori eradication therapy to standard NASH therapy appears to be beneficial for the management of people diagnosed with dyspeptic non-diabetic NASH.